Home > News > 454 Life Sciences and Roche Enter Exclusive World-Wide Agreement
May 12th, 2005
454 Life Sciences and Roche Enter Exclusive World-Wide Agreement
Abstract:
454 Life Sciences and Roche today announced they have entered into an exclusive 5-year world-wide agreement for the promotion, sale, and distribution of 454 Life Sciences' nanotechnology-based Genome Sequencing Systems, including proprietary kits and reagents. The technology used in the 454 Genome Sequencing System enables researchers to sequence up to 100 times faster than current commercial platforms.
Source:
prnewswire
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
High-tech 'paint' could spare patients repeated surgeries March 8th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||